Bottom line
CURE vs HIBS: the short answer
CURE (Direxion Daily Healthcare Bull 3X ETF) and HIBS (Direxion Daily S&P 500(R) High Beta Bear 3X ETF) are both etfs.
But CURE is far broader, holding 67 positions to 8 for HIBS, so beyond the top names it adds exposure HIBS doesn't have.
CURE is cheaper at 0.94% vs 1.06% — a difference of $12 a year per $10,000 invested.
Over five years, CURE returned +8.6% a year vs −55.6% for HIBS.
Updated Nov 19, 2026
CURE vs HIBS side by side
| CURE | HIBS | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Direxion | Direxion |
| Category | Leveraged & Inverse | Leveraged & Inverse |
| Expense ratio | 0.94% | 1.06% |
| Annual cost per $10k | $94 | $106 |
| 10-yr cost on $10k (prospectus) | $1,155 | $1,347 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +22.9% | −72.4% |
| 5-yr return (annualized) | +8.6% | −55.6% |
| 10-yr return (annualized) | +13.6% | — |
| Best quarter | +46.9% | +74.7% |
| Worst quarter | −45.8% | −79.0% |
| Net assets (fund) | $171.7M | $22.6M |
| Number of holdings | 67 | 8 |
| Portfolio turnover | 1% | % |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | CURE | HIBS | Difference |
|---|---|---|---|
| 2025 | +22.9% | −72.4% | +95.3% |
| 2024 | −8.5% | −26.6% | +18.1% |
| 2023 | −9.8% | −63.0% | +53.2% |
| 2022 | −20.4% | −7.6% | −12.8% |
| 2021 | +87.4% | −75.2% | +162.7% |
| 2020 | +5.1% | −91.6% | +96.7% |
Source: Fund prospectus bar charts
Holdings overlap
6 of CURE's top 25 holdings also appear in HIBS's top 8.
| Holding | CURE | HIBS |
|---|---|---|
| Dreyfus | 18.79% | 48.43% |
| N/a | 8.28% | 1.18% |
| Goldman Sachs Liq Es Fd A | 8.19% | 26.65% |
| Goldman Financial | 7.51% | 28.96% |
| N/a | 3.34% | 1.18% |
| N/a | 1.12% | 1.18% |
Source: SEC Form N-PORT
CURE top 10
- Dreyfus — 18.79%
- Eli Lilly & Company — 10.41%
- N/a — 8.28%
- Goldman Sachs Liq Es Fd A — 8.19%
- Goldman Financial — 7.51%
- Johnson & Johnson — 7.07%
- Abbvie Inc — 5.08%
- Unitedhealth Group Inc — 4.31%
- Merck & Company Inc — 3.68%
- N/a — 3.34%
HIBS top 10
- Dreyfus — 48.43%
- Goldman Financial — 28.96%
- Goldman Sachs Liq Es Fd A — 26.65%
- N/a — 5.90%
- N/a — 2.40%
- N/a — 2.21%
- N/a — 1.19%
- N/a — 1.18%
FAQ
What is the difference between CURE and HIBS?
Which is cheaper, CURE or HIBS?
Should I own both CURE and HIBS?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.